Price movement over the last 24 hours
Agilysys Inc vs ClearPoint Neuro Inc — how do they compare? Agilysys Inc trades at $107.67 (market cap $3.18B), while ClearPoint Neuro Inc trades at $17.13 (market cap $524.82M). The key difference: Agilysys Inc is far larger — about 6.1× ClearPoint Neuro Inc's market cap, and Agilysys Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | CLPT | |
|---|---|---|
Market Cap | $3.18B | $524.82M |
Sector | Technology | Health |
52-Week High | $141.12 | $29.60 |
52-Week Low | $62.19 | $8.66 |
Enterprise Value | $3.08B | $552.81M |
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.
The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.
ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.
The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.
Trailing returns across standard periods
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →